Curriculum vitae personal history name
D. Education Administration
Download 203.61 Kb.
|
- Navigate this page:
- E. Mentorship
- Research Support
D. Education Administration1996-2004 Co-organizer, weekly HIV Research Seminar/Journal Club, Colorado Center for AIDS Research, University of Colorado Denver School of Medicine 1997-2003 Co-organizer, weekly Infectious Disease Grand Rounds, University of Colorado Denver School of Medicine 2005-present Program Director, Colorado HIV Research Training Program, University of Colorado Denver School of Medicine 2006-2008 Global Health Tract Steering Committee, University of Colorado Denver School of Medicine 2008-present Course Co-Director, Scientific Grant Review Process – Masters (CLSC 6300), University of Colorado Denver School of Medicine 2008-present Course Co-Director, Scientific Grant Review Process – Doctoral (CLSC 7300), University of Colorado Denver School of Medicine E. Mentorship1995-1997 Research Preceptor for Cheryl K. McDonald, M.D., Clinical and Research Fellow, Division of Infectious Diseases, University of Colorado Denver School of Medicine. 1997-1998 Research Preceptor for Lisa Fitzpatrick, M.D., Clinical and Research Fellow, Division of Infectious Diseases, University of Colorado Denver School of Medicine. 1998-1999 Thesis Committee for Anton McCaffery, Ph.D. Candidate, Department of Chemistry and Biochemistry, University of Colorado Boulder 1998-2000 Thesis Committee for Qing Wang, Ph.D. Candidate, Department of Biochemistry and Molecular Genetics, University of Colorado Denver School of Medicine 1998 Research Preceptor for Amit Bhatt, Student, University of Colorado Denver Diversity Summer Scholars Program 1998-2000 Research Preceptor for Jia-peng Ruan, Ph.D., Research Fellow, Division of Infectious Diseases, University of Colorado Denver School of Medicine, 1999 Research Preceptor for Kayla Sheets, Student, Smith College Summer Internship Program 1999-2004 Research Preceptor for Moira Hagen, Ph.D., Research Fellow, Division of Infectious Diseases, University of Colorado Denver School of Medicine. 1999-2000 Thesis Committee for M.K. Smith, Ph.D. Candidate, Molecular Biology Program, University of Colorado Denver School of Medicine 1999-2003 Thesis Committee for Sean Bennett, Ph.D. Candidate, Department of Immunology, University of Colorado Denver School of Medicine 2000 Examination Committee for Nina Frank, Ph.D. Candidate, Department of Microbiology, University of Colorado Denver School of Medicine 2000 Beth Murrill, Student, Colorado Rocky Mountain School Senior Apprenticeship Project 2001-2005 Thesis Advisor for Christina Meadows, Ph.D. Candidate, Department of Microbiology, University of Colorado Denver School of Medicine 2001-2003 Research Preceptor for James Neid, M.D., Clinical and Research Fellow, Division of Infectious Diseases, University of Colorado Denver School of Medicine 2001-2004 Research Preceptor for Tiffany White, Ph.D., Research Fellow, Division of Infectious Diseases, University of Colorado Denver School of Medicine 2001-2005 Thesis Committee for Eli Boritz, Ph.D. Candidate, Department of Immunology, University of Colorado Denver School of Medicine 2002 Examination Committee for Jessalynn Hall, Ph.D. Candidate, Department of Microbiology, University of Colorado Denver School of Medicine 2003 Examination Committee for Daniel Felmlee, Ph.D. Candidate, Molecular Biology Program, University of Colorado Denver School of Medicine 2003 Examination Committee for Erin Buckingham, Ph.D. Candidate, Department of Microbiology, University of Colorado Denver School of Medicine 2004-2005 Research Advisor for Amanda Parker, Cherry Creek High School Honors Program 2005-2006 Research Mentor for Amie Meditz, M.D., Research Fellow, Division of Infectious Diseases, University of Colorado Denver School of Medicine 2005-2006 Research Advisor for Cozette Stahl, Under Graduate Student, Colorado College 2006-2007 Research Advisor for Rachel Kelley, Cherry Creek High School Honors Program 2006-2007 Research Mentor for Genaro Fernandez, Medical Student, Global Health Track, University of Colorado Denver School of Medicine 2007-2010 Research Mentor for Bradley Nelson, Medical Student, Global Health Track, University of Colorado Denver School of Medicine 2007-2008 Research Mentor for Zuzanna Czernik, Medical Student, University of Colorado Denver School of Medicine 2007-2010 Research Mentor for Anna Neumeier, Medical Student, University of Colorado
2007 Research Mentor for Jennifer Lesh, GEMS program, University of Colorado Denver School of Medicine 2008-present Research Mentor for Kristine Erlandson, M.D., Infectious Disease Fellow 2009-present Research Mentor for Jose Castillo, M.D., Assistant Professor of Medicine 2010-present Research Mentor for Christal Davis, Lab Coats Program
1. NIH 1F32AI08764 "Resistance of HIV-1 to Anti-retroviral Agents" Fellow: Thomas B. Campbell, M.D. Dates and direct costs of entire project: 10/01/92-04/30/93; $33,800 2. Colorado Institute for Research in Biotechnology "Ribozymes as Molecular Therapies for Human Immunodeficiency Virus Infection" P.I. Robert T. Schooley Role on Project: Co-Investigator Dates and cost of project: 07/31/92-06/30/93; $15,000 3. NIH 1K11AI01159 "In Vivo Selection of Anti-HIV-1 Ribozymes" P.I: Thomas B. Campbell, M.D. Dates and cost of project: 05/01/93-04/30/98; $476,637
P.I. Robert T. Schooley Role on Project: Co-Investigator Dates and cost of project: 01/01/94-12/31/96; $1,939,086 5. Colorado RNA Center "The Effect of HIV-1 mRNA Secondary Structure on the Effectiveness of HIV-1 Ribozymes" P.I. Thomas B. Campbell Dates and cost of project: 07/01/96-06/30/97; $35,000
P.I. Thomas B. Campbell Dates and cost of project: 05/01/97-04/30/00; $611,822
P.I. Thomas B. Campbell Dates and costs of project: 07/01/97-06/30/98; $15,000
P.I. Thomas B. Campbell Dates and direct costs of entire project: 07/01/98-06/30/03; $854,939
P.I. Thomas B. Campbell Dates and costs of project: 09/30/99-09/29/03; $75,600
P.I. Robert T. Schooley Role on Project: Co-Investigator Dates and yearly direct costs of project: 01/01/99-10/31/04; $1,512,908 11. University of Colorado Cancer Center Quantitative Analysis of Human Herpesvirus 8 Gene Expression P.I: Thomas B. Campbell Dates and cost of project: 01/01/00-12/31/00; $20,000
P.I. Robert T. Schooley Role on Project: Project Leader for Virology Project Dates and costs of project (Virology Project only): 07/01/01-04/30/03; $359,829 13. NIH/AACTG contract 200VC005 “Virology Support Laboratory” P.I. Daniel R. Kuritzkes Role on Project: Co-Investigator Dates and cost of project: 01/01/00-05/31/02; $1,083,00 14. American Foundation for AIDS Research “Latent HIV-1 Induced by Stem Cell Mobilization” P.I. Thomas B. Campbell Dates and costs of project: 06/01/01-08/31/02; $72,000
P.I. Thomas B. Campbell Dates and costs of project: 01/01/02-6/30/03; $16,116
P.I. Thomas B. Campbell Dates and cost of project: 12/01/02-06/30/03; $36,565
P.I. Edward Janoff Role on Project: Director, CFAR Virology Core Dates and cost of project (Virology Core only): 07/01/03-04/30/08; $1,264,293 18. Glaxo Smith Kline COL30512 “A Pilot Study of the Effects of Highly Active Antiretroviral Therapy on Kaposi’s Sarcoma in Zimbabwe” P.I. Thomas B. Campbell Dates and cost of project: 07/01/03-12/30/05; $147,211
P.I. Thomas B. Campbell Dates and cost of project: 07/01/03-12/30/05; $13,157
P.I: Thomas B. Campbell Dates and cost of project: 07/01/03-06/30/04; $45,778
P.I. Elizabeth Connick Role on Project: Project Leader for Project 5, “Role of Fitness of Transmitted Virus” Dates and cost of project (Project 5 only): 09/29/03-09/28/08; $1,311,362 22. NIAID/AACTG contract “AACTG Zimbabwe International Clinical Trials Unit” P.I. Thomas B. Campbell Dates and cost of project: 12/01/03-12/31/04; $89,542
Role on Project: Associate Program Director Dates and yearly direct costs of project: 12/1/02 – 4/30/08; $6,496,116
P.I. Thomas B. Campbell Dates and costs of entire project: 01/01/03-12/31/04; $2,500
P.I. Thomas B. Campbell Dates and cost of project: 1/01/05-12/31/05; $1,836,247
P.I. Thomas B. Campbell Dates and cost of project: 07/01/05-06/30/08; $451,360
P.I. Thomas B. Campbell Dates and cost of project: 07/01/05-09/30/12; $1,340,698
P.I. Thomas B. Campbell Dates and cost of project: 1/01/06-12/31/06; $1,849,386
P.I. Thomas B. Campbell Dates and cost of project: 01/01/05-12/31/07; $50,000
P.I. Thomas B. Campbell Dates and cost of project: 04/01/05-06/30/07; $74,838
P.I. Brad Navia (Tufts University) Role on Project: Principal Investigator for Colorado site Dates and cost of project: 05/23/05-04/30/08; $156,000 32. NIH/NIAID R01 AI071820 “Hepatitis B Treatment and HIV Infection in Resource-Limited Settings” P.I. Chloe Thio (Johns Hopkins University) Role on Project: Co-investigator Dates and total cost of project: 07/01/06-06/30/11; 33. NIH U01 AI069450 “Colorado AIDS Clinical Trials Unit” P.I. Thomas B. Campbell Dates and total cost of project: 02/01/2007 - 11/30/2013; $7,620,295
P.I. Constance Benson (University of California San Diego) Role on Project: Vice Chair of the Optimization of Management Scientific Committee Dates and total costs of project 03/01/07-05/31/09; $20,000
P.I. Ron Sokol Role on Project: Medical Director, University of Colorado Hospital Clinical Translational Research Center Dates and total cost of project: 06/01/08-05/31/13; $76,000,000 36, NIH/NIAID R01 AI80417 “Impact of Malnutrition on HIV Treatment Failure in Resource-Limited Settings” P.I. Amita Gupta (Johns Hopkins University) Role on Project: Co-Investigator Dates and total cost of project: 04/01/09 – 03/31/13; $375,723 37. Social Scientific Systems Subcontract “AIDS Clinical Trials Group” P.I. Constance Benson (University of California San Diego) Role on Project: Chair of the Optimization of Management Scientific Committee Dates and total costs of project 06/01/09-05/31/11; $64,000
P.Is. Andrew Fontenot, Thomas Campbell, Sonia Flores, Rob Knight Dates and total cost of project: 09/23/09 – 07/31/14; $4,011,474
P.I. Thomas Campbell Dates and total cost of project: 01/01/10-12/31/10; $215,000
P.I. Lawrence Corey (University of Washington) Role on Project: Dr. Campbell is the PI of the University of Colorado subcontract for implementation of the HVTN 505 protocol, Dates and total cost of project: 06/01/10-05/31/12; $955,165 41. GlaxoSmithKline “Nucleosides and Inflammation, Coagulation and Endovascular Function” P.I. David Whol (University of North Carolina) Role on Project: Dr. Campbell is the University of Colorado PI for this multicenter investigator-inititated study. Dates and total cost of project: 07/01/10-12/01/10; $50,750 42. NIH/FIC R24 TW008881 “Novel Education Clinical Trainees and Researchers (NECTAR) Program” P.Is. James Hakim, Michele Barry, Thomas Campbell, Peter Mason Dates and total costs of project: 09/27/10-08/31/15; $ 8,184,000
1. Chiron Technologies CS-GT003 "A Phase II, Randomized, Double Blind Placebo Controlled Study of Combination Drug Antiretroviral Therapy to Include a Reverse Transcriptase Inhibitor and a Protease Inhibitor Plus HIV-IT(V) or Placebo in HIV Patients with CD4 Counts 100, and HIV RNA 1K, but 100K" P.I. Thomas B. Campbell Dates and costs of project: 05/14/97-11/13/97; $9,551 2. Roche/Trimeris T20-301/NV16054,“Phase III Randomized Active-controlled Study Assessing the Efficacy and Safety of T-20/RO29-9800 in Combination with Optimized Background versus Optimized Background Alone in Patients with HIV-1” P.I: Thomas B. Campbell Dates and costs of project: 08/01/02-06/01/04; $83,141.31
P.I. Thomas B. Campbell Dates and costs of project: 7/02-1/05
P.I. Thomas B. Campbell Dates and cost of project: 7/02-6/03
P.I. Thomas B. Campbell Dates and costs of entire project: 07/22/04 – 07/21/06; $51,116
P.I. Thomas B. Campbell Dates and cost of project: 06/22/04-06/21/07; $40,047
P.I. Thomas B. Campbell Dates and cost of project: 10/01/03-09/30/06; $43,058
P.I. Thomas B. Campbell Dates and cost of project: 01/01/05-01/01/08; $134,850
P.I. Thomas B. Campbell Dates and cost of project: 03/01/05-03/01/10; $88,844
P.I. Thomas B. Campbell Dates and cost of project: 06/01/05-06/01/10; $ 59,730
P.I. Thomas B. Campbell Dates and cost of project: 07/01/05-07/01/10; $7,875
liquid formulation with respect to the lyophilized formulation of BAY 50-4798” P.I. Thomas B. Campbell Dates and cost of project: 04/01/04-12/31/05; $128,966 13. Tibotec Pharmaceuticals TMC125-C216 “A Phase III Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Including TMC114/RTV and an Investigator-Selected OBR Regimen in HIV-1 Infected Patients with Limited Treatment Options.” P.I. Thomas B. Campbell Dates and total cost of project: 11/18/05-11/01/10; $52,000
P.I. Thomas B. Campbell Dates and total cost of project: 11/05 – 11/10; $5,025
P.I. Thomas B. Campbell Dates and total cost of project: 09/01/06 to 08/31/10; $62,400
P.I. Thomas Campbell Dates and total costs of project: 01/12/06-01/12/07; $9,739
P.I. Thomas B. Campbell Dates and total cost of project: 06/07 – 01/10; $93,231
P.I. Thomas Campbell Dates and total costs of project: 06/07 – 03/10; $133,254
P.I. Thomas Campbell Dates and total costs of project: 01/09-02/10; $297,142
P.I. Thomas Campbell Dates and total costs of project: 07/01/10 – 12/20/13; $98,700
P.I. Thomas Campbell Dates and total costs of project: 06/01/09 – 02/13/12; $59,382
P.I. Thomas Campbell Dates and total costs of project: 10/01/10 – 09/30/11; $194,160
P.I. Thomas Campbell Dates and total costs of project: 09/01/11-08/31/13;
R01 AI100026, “Strategies to Improve Kaposi's Sarcoma Outcomes in Zimbabwe” Role on Project: Principal Investigator Dates and cost of project: 04/01/2012-03/31/2015; $3,000,000 D. Leadership in Multicenter Research Studies 2003-present Co-Chair, A5175 “A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor- and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Individuals from Resource-Limited Settings (PEARLS) Trial”. This study is funded by the NIAID. 2006-2010 Vice Chair, “An Open-Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute or Recent HIV-1 Infection in Zimbabwe and the United States”. This study was funded by the NIAID. 2008-present Co-Chair, A5264 “A Randomized Comparison of Antiretroviral Therapy Alone or with Delayed Chemotherapy versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS”. This study is funded by the NIAID and the NCI. 2008-present Vice Chair, A5263 “A Randomized Comparison of Three Chemotherapy Regimens as an Adjunct to Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings”. This study is funded by the NIAID and the NCI. BIBLIOGRAPHY A. Original Articles in Peer-Reviewed Journals 1. Lueking DR, Campbell TB, Burghardt RC. Light induced division and genomic synchrony in phototropically growing Rhodopseudomonas sphaeroides. J Bact. 1981;146:790 797. 2. Campbell TB, Lueking DR. Long chain fatty acid assimilation by Rhodopseudomonas sphaeroides. J Bact. 1983;153:782 790. 3. Campbell TB, Lueking DR. Light mediated regulation of phospholipid synthesis in Rhodopseudomonas sphaeroides. J Bact. 1983;155:806 816. 4. Campbell TB, Kaufman L, Cook JL. Aspergillosis of the prostate associated with an indwelling catheter: Case report and review. Clin Infect Dis. 1992;14:942-944. 5. Campbell TB, Young RK, Eron JJ, D'Aquila RT, Tarpley WG, Kuritzkes DR. Inhibition of human immunodeficiency virus type-1 replication in vitro by the bisheteroarylpiperazine atevirdine (U- 87201E) in combination with zidovudine or didanosine. J Infect Dis. 1993;168:318-326. 6. Campbell TB, Cech, TR. Identification of ribozymes within a ribozyme library that efficiently cleave a long substrate RNA. RNA. 1995;1:598-609. 7. Campbell TB, Cech, TR. Mutations in the Tetrahymena ribozyme internal guide sequence: Effects on docking of the P1 helix into the catalytic core and correlation with catalytic activity. Biochemistry. 1996;35:11493-11502. 8. Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich M, Phair J, Pottage JC, Collier A, Kahn J, and the ACTG 184 Protocol Team. A phase 1 study of combination therapy with L 697,661 and zidovudine. J Acquir Immune Defic Syndr. 1996; 12:363-370. 9. Campbell TB, McDonald CK, Hagen M. The Effect of Structure in a Long Substrate RNA on ribozyme cleavage efficiency. Nucleic Acids Research. 1997;25:4985-4993. 10. Zhang X, Fitzpatrick L, Campbell TB, Badaro R, Schechter M, de Fatimo Melo M, Brites C, Sampaio DP, Schooley RT. Comparison of the prevalence of antibodies to human herpesvirus 8 (Kaposi's Sarcoma-associated herpesvirus) in Brazil and in the United States. J Infect Dis 1998;178:1488-91. 11. Campbell TB, Fitzpatrick L, MaWhinney S, Zhang X, and Schooley RT. Human Herpesvirus 8 (Kaposi's Sarcoma-Associated Herpesvirus) in men receiving treatment for HIV-1 infection. J Acquir Immune Defic Syndr. 1999; 22:333-340. 12. Campbell TB, Borok M, Gwanzura L. HHV-8 peripheral blood virus load and the titer of antibodies against HHV-8. N Engl J Med. 1999;341:1241-1242. 13. Campbell TB, Sevin A, Coombs RW, Peterson G, Rosandich M, Kuritzkes DR, Landay A, Wong R, Ambruso D, Mladenovic J, Miles S, Pomerantz R, Schooley RT and the ACTG 285 Study Team. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoetic progenitor cells. Blood 2000; 95:48-55. 14. Schooley RT, Mladenovic J, Sevin A, Chiu S, Miles SA, Pomerantz R, Campbell TB, Bell D, Ambruso D, Wong R, Landay A, Coombs RW, Fox L, Jacovini J and the ACTG 285 Study Team. A Pilot study of CD34+ stem cell mobilization and harvesting from the peripheral blood of persons with HIV-1 infection: reduced mobilization in advanced disease. J Infect Dis 2000;181:148-157. 15. White IE, Campbell TB. Quantitation of cell-free and cell-associated Kaposi's sarcoma-associated herpesvirus DNA by real-time PCR. J Clin Microbiol 2000;38:1992-1995. 16. Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, Guzda I, Fitzpatrick L, Schooley RT. Relationship of Kaposi's sarcoma-associated herpesvirus peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000; 14:2109 2116. 17. Connick E, Schlichtemeier RL, Purner MB, Schneider KM, Anderson DM, MaWhinney S, Campbell TB, Kuritzkes DR, Douglas JM, Judson FN, Schooley RT. Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion. J Infect Dis 2001;184:1465-9. 18. Campbell TB, Borok M, White IE, Gudza I, Ndemera B, Taziwa A, Weinberg A, and Gwanzura L. Relationship of Kaposi’s Sarcoma-Associated Herpesvirus Viremia and Kaposi’s Sarcoma Disease in Zimbabwe. Clin Infect Dis 2003; 36:1144-1151. 19. Bull TM, Cool CD, Yeager M, Parr J, Neid J, Campbell TB, Voelkel NF, Badesch D. Primary pulmonary hypertension, Castleman’s Disease and HHV-8. Eu Resp J 2003;22:403-407. 20. Campbell TB, Schneider K, Wrin T, Petropoulos CJ, Connick E. Relationship between HIV-1 replication rate and plasma virus load. J Virol 2003:77:12105-12122. 21. Campbell TB, Rapaport R, Schooley RT, Kuritzkes DR. Increased Replication of HIV-1 minor variants during hematopoietic stem cell mobilization with filgrastim. J Infect Dis 2004;189:257–266. 22. Neid JM, Schooley RT, Campbell TB. Kaposi’s sarcoma-associated herpesvirus viremia during hematopoietic stem cell mobilization with filgrastim. Am J Hematol 2004;74:410-412. 23. Connick E, Kane MA, White IE, Ryder J, Campbell TB. Immune reconstitution inflammatory syndrome (IRIS) to Kaposi’s sarcoma during potent antiretroviral therapy. Clin Infect Dis 2004;39:1852-1855. 24. Campbell TB, Staskus KA, Folkvord J, White IE, Neid J, Zhang X-Q, Connick E. Persistence of Kaposi’s sarcoma-associated herpesvirus (KSHV) infected cells in HIV-1 co-infected persons without KSHV-associated diseases. J Infect Dis 2005; 191:367-371. 25. Campbell TB, Shulman N, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan T, Kuritzkes DR. Antiviral activity of lamivudine in salvage therapy of multidrug-resistant human immunodeficiency virus type 1 infection. Clin Infect Dis 2005;41:236-242. 26. Koeppe JR, Campbell TB, Rapaport EL, Wilson CC. HIV-1 specific CD4+ T cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia. J Acquir Immune Defic Syndr. 2006;41:140-148. 27. Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kellecher AD, Kaldor J, Routh JP, Campbell TB, Rosenberg E, Schafer K, Wood K, Weidler J, Bates M, Grant RM. Greater CD4+ T cell responses during antiretroviral therapy associates with lower viral pol replication capacity. AIDS 2006;20:2123-2125. 28. Gripshover B, Santana J, Ribaudo H, Gerber J, Campbell TB, Hogg E, Jarocki B, Hammer S, and Kuritzkes D. A randomized, placebo-controlled trial of amdoxovir vs placebo with enfuvirtide plus optimized background therapy for HIV-infected subjects failing current therapy (AACTG 5118). Antiviral Therapy. 2006;11:619-23. 29. Meditz AL, Borok M, Gudza I, Ndemera B, Gwanzura L, Campbell TB. Gender Differences in AIDS-associated Kaposi’s Sarcoma in Harare, Zimbabwe. J Acquir Immune Defic Syndr 2007;44:306–308. 30. Boritz E, Rapaport E, Campbell TB, Koeppe JR, Wilson CC. CD4+ T Cell Targeting of HIV-1 peptide sequences present in vivo during chronic, progressive HIV-1 disease. Virology 2007;361:34-44. 31. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, De Smedt G, Baeten B, Beets G, Sinha R, Woodfall B on behalf of the DUET-2 study group. DUET-2: 24 week results of a randomised double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 591 treatment-experienced HIV-1 infected patients. Lancet 2007;370:39-48. 32. Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic evaluation of allele-specific real time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Meth. 2007;146:136-146. 33. White T, Hagen M, Gudza I, White IE, Ndemera B, Gwanzura L, Borok M, Campbell TB. Genetic diversity of the Kaposi’s sarcoma herpesvirus K1 protein in Zimbabwe. J Clin Virol 2008;42:165–171. 34. Bull TM, Meadows CA, Coldren C, Moore M, Nana-Sinkam SP, Campbell TB, Geraci MW. Human herpesvirus 8 infection of primary pulmonary microvascular endothelial cells. Am J Resp Cell Molec Biol 2008;39:706-16. 35. Campbell TB, Borok M, Ndemera B, Fiorillo S, White IE, Zhang XQ, Machekano R, Katzenstein D, Gwanzura L. Lack of Evidence for Frequent Heterosexual Transmission of Human Herpesvirus 8 (HHV-8) in Zimbabwe. Clin Infect Dis 2009;48:1601-8. 36. Letang E, Almeida J, Ayala E, Miró JM, White IE, Carrilho C, Bastos R, Nhampossa T, Gascón J, Menéndez C, Campbell TB, Alonso P, Naniche D. Predictors of immune reconstitution inflammatory syndrome associated with Kaposi sarcoma (IRIS-KS) in a rural area of Mozambique. JAIDS 2010;53:589-597. 37. Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A, Paul R, Taylor M, Thompson P, Algers J, Brown M, Zhong J, Campbell T, Singer E, McMahon D, Tso Y, Yiannoutsos CT, Navia B and the HIV Neuroimaging Consortium. Effects of nadir CD4 count and duration of HIV infection on brain volumes in the highly active antiretroviral therapy era. J Neuro Virol 2010;16:1–8. 38. Borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, Watson H, Gwanzura L, Schooley RT, Campbell TB. Evaluation of plasma human Herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy of AIDS-related Kaposi’s sarcoma in Zimbabwe. Clin Infect Dis 2010;51:342–349. 39. Firnhaber C, Smeaton L, Saukila N, Flanigan T, Gangakhedkar R, Kumwenda J, La Rosa A, Kumarasamy N, De Gruttola V, Hakim JG, Campbell TB. Comparisons of anemia, thrombocytopenia and neutropenia at initiation of antiretroviral therapy in Africa, Asia and the Americas. Int J Infect Dis. 2010;14:e1088–1092. 40. Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia B. HIV Neuroimaging Consortium. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011 13;25:625-33. 41. Tate DF, Sampat M, Fiecas M, Hogan J, Harezlak J, Russell T, Conley J, Price J, McCaffrey D, Taylor M, Schifitto G, Zhong J, Daar ES, Alger J, Brown M, Singer E, Campbell T, McMahon D, Tso Y, Matesan J, Letendre S, Siqueiros L, Paulose, S, Gaugh M, Tripolica C, Janetta Gotts, Paul RH, Yiannoutsos C, Bigler ED, Cohen RA, Guttmann CRG, Navia B for the HIV MRS Consortium. Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies. J Neuro Virol 2011;17:368-79. 42. Safren S, Celentano D, Smeaton L, Hendriksen E, Hosseinipour M, Barnett R, Guanira J, Flanigan T, Kumarasamy N, Klingman K, Swann E, De Gruttola V, Campbell T for the PEARLS Study Team. Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world. AIDS and Behavior 2011 Apr 16. [Epub ahead of print]. 43. Grinsztejn B, Smeaton L, De Gruttola V, Barnett R, Klingman K, Hakim J, Flanigan T, Kumarasamy N, Campbell T, Currier J and the PEARLS study team of the ACTG. Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4 cell count. Antivir Ther. 2011;16(7):1057-1062. 44. Nahid P, Saukkonen J, Mac Kenzie W, Johnson JL, Phillips P, Bliven E, Andersen J, Belisle J, Boom H, Campbell T, Eisenach K, Hafner R, Lennox J, Leutkemeyer a, Livnat D, Makhene M, Swindells S, Villarino EM, Weiner M, Benson C, Burman W. Tuberculosis biomarker and surrogate endpoint research roadmap: Summary of Joint CDC/NIH Tuberculosis Biomarkers Workshop. Am J Resp Critical Care Med. (in press). 45. Robertson K, Kumwenda J, Supparatpinyo K, Evans S, Jiang H, Campbell TB, Price RW, Murphy R, Hall C, Marra C, Marcus C, Berzins B, Masih R, Santos B, Silva MT, Kumarasamy N, Tripathy S, Kanyama C, Hosseinipour M, Montano S, La Rosa A, Amod F, Sanne I, Firnhaber C, Hakim J, Brouwers P, and the AIDS Clinical Trials Group. A multinational study of neurocognitive performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neuro Virol 2011;17:438–447. 46. Meditz AL, Haas MK, Folkvord JM, Melander K, Young R, McCarter M, MaWhinney S, Campbell TB, Weinberg A, Lie Y, Coakley E, Levy DN, Connick E. HLA-DR+CD38+CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo. J Virol 2011;85:10189–10200. 47. Castillo-Mancilla J, Allshouse A, Collins C, Hastings-Tolsma, M, Campbell TB, MaWhinney S. Differences in Sexual Risk Behavior and HIV/AIDS Risk Factors among Foreign-born and US-born Hispanic women. J Immigrant Minority Health (in press) Directory: FIMS -> Content -> faculty faculty -> Stephanie Watson Mayer, md education and Surgical Training Download 203.61 Kb. Share with your friends:
|